For more than two decades, the European Union was the global fortress of anti-GMO sentiment, governed by a precautionary principle that prioritized risk avoidance over agricultural innovation. This era was defined by the 2001 GMO Directive, a rigid set of rules that made the commercialization of biotech crops nearly impossible, although the EU continued importing large volumes of GMO crops for animal feed. The tension reached a breaking point in 2018, when the European Court of Justice ruled that modern, targeted gene editing, a form of mutagenesis, fell under the same restrictive transgenic laws. Even minor genetic changes made without introducing foreign DNA were treated as legally equivalent to older genetic modification. That preserved a regulatory environment many researchers, breeders, and farm groups argued was outdated and poorly matched to newer breeding tools.
A combination of forces led to a rethink of this restrictive policy. Some agricultural technology companies began moving research projects to the United States and other countries with more flexible rules. Climate pressure, food security concerns, and the European Green Deal also changed the debate. The Farm to Fork strategy called for a 50 percent reduction in pesticide use, but that goal was difficult to square with a legal system that kept many crop-resilience tools locked inside the older GMO approval route. The European Commission began a multi-year effort to modernize the law, proposing a new framework in July 2023 for plants developed through mutagenesis and cisgenesis.
That position has now changed for plants. Parliament has adopted new rules in June 2026 for new genomic techniques, or NGTs, that keep EU oversight but divide gene-edited plants into two legal categories. The system moves the plant side away from a simple question about how the crop was made and toward a narrower question about what kind of genetic change the final plant contains.
The first category, NGT-1, covers plants with a limited number and type of changes that could also have occurred through conventional breeding. Once a plant has been verified for NGT-1 status, it will be treated like a conventional plant rather than sent through the full GMO approval route. That does not mean invisible commercialization. Plant varieties containing or derived from an NGT-1 plant will be listed in a public EU database, and seed bags and reproductive material will have to be labeled NGT-1 so farmers can see what they are buying.
The second category, NGT-2, covers plants with more extensive or complex genetic changes. These plants remain under the existing GMO rules. They require risk assessment and authorization before commercialization in the EU. Parliament also drew a political line around certain traits: plants engineered for herbicide tolerance or to produce insecticidal substances cannot qualify as NGT-1, even if the underlying edit might otherwise look limited. Those products move into the stricter NGT-2 lane.
The approval pathway is therefore not deregulation in the simple sense. Developers seeking NGT-1 status must first pass verification against the category criteria. If they clear that test, the plant moves into a conventional-style market route, with database listing and seed labeling. If they do not, the plant remains subject to the stricter GMO system. NGT-2 plants will still face traceability, labeling, risk assessment, and authorization requirements, and EU countries may restrict or prohibit cultivation of authorized NGT-2 crops on their territory.
The law also matters for trade. The same categories will apply to plants originating in Europe and to imported plants. That is significant because several NGT products are already commercialized or in advanced development outside the EU, including low-gluten wheat, pathogen-resistant potatoes, and drought-tolerant maize. The new framework gives the EU a way to assess those products through its own category system rather than treating all gene-edited plants alike under the older GMO route. It also reflects a competitiveness argument that has become more prominent in Brussels: farmers and breeders should not be left dependent on imported innovation if Europe wants crops that are more climate resilient, pest resistant, higher yielding, and less dependent on pesticides.
Organic farming remains outside the opening. No NGT plants will be allowed in organic production. At the same time, technically unavoidable presence of NGT-1 material will not automatically count as non-compliance for organic operators. That compromise keeps organic farming formally separate while recognizing that total physical separation may become difficult once NGT-1 seed and commodity channels exist. The Commission will also have to assess whether the regulation creates administrative, economic, or practical burdens for organic operators, including burdens linked to consumer perception.
Patents remain one of the most politically sensitive parts of the reform. Opponents of the law, especially environmental and organic groups, argue that easing many NGT-1 plants while allowing patent protection could strengthen the hand of large seed companies. Breeders and farm groups worry about access, licensing costs, and accidental infringement. Parliament’s final framework allows patent protection for NGTs, except for traits or sequences that occur in nature or are produced by biological means. It also includes safeguards intended to prevent market concentration, protect affordability, ensure fair access for farmers, and preserve farmers’ right to save and replant seed.
The legal status has changed since the earlier draft. The NGT regulation is no longer merely waiting for Parliament as the final legislative step. Parliament has adopted the new rules. The regulation will enter into force 20 days after publication in the EU Official Journal and will apply two years later. That means the reform is adopted, but its practical market effects will still be delayed while regulators, breeders, seed companies, farmers, and member states prepare for implementation.
The animal side remains separate. The new regulation is about plants developed with certain new genomic techniques and their food and feed uses. It does not create a new route for gene-edited livestock, poultry, fish, or aquaculture. Gene-edited animals remain under the existing EU GMO system, where food-chain use would face full authorization, risk assessment, traceability, and labeling requirements. The welfare debate is also different from the crop debate. Critics worry that animal gene editing could be used to adapt animals to intensive production systems, while aquaculture raises additional concerns about escape, interbreeding, and ecological effects. The EU has not adopted a dedicated lighter framework for food-producing animals.
In sum, the EU is moving from a default position where gene-edited plants were treated under GMO law toward a two-tier framework that will ease market access for some plants while keeping stricter controls for others. The reform does not open the door to all gene-edited crops. It creates a case-by-case structure: NGT-1 plants receive a lighter conventional-style route with public listing and seed labeling, while NGT-2 plants, herbicide-tolerant crops, and insecticidal plants remain in the stricter lane. The system is plant-specific, excludes organic production, keeps animal biotechnology outside the reform, and will not fully apply until two years after the regulation enters into force.
NGO Reaction
Euroseeds, a non-profit seed industry association, called the agreement a “balanced compromise” crucial for fostering innovation and competitiveness within the EU seed sector. While industry groups view the legislation as a “modernization,” the NGO community views it as a “surrender” to biotech giants, with the battle now shifting toward how these rules will be implemented at the national level over the next 24 months.
The reaction from European civil society has been overwhelmingly critical, characterized by a fundamental distrust of the “product-based” shift. In an attempt to block the legislation, a coalition of more than one hundred civil society associations and food companies argued in early 2025 that deregulation “poses a serious threat to the business of European small- and medium-size breeders and farmers, and to the organic and GMO-free sectors.” After the legislation gained traction in the European Parliament, Greenpeace and Foodwatch spearheaded a coalition statement from dozens of advocacy groups. They frame the legislation as a dangerous shift away from the precautionary principle and toward unforeseen legal and market risk for farmers and nature. They continue to demand full traceability and labelling across the value chain, vehemently opposing the plan to treat NGT 1 plants as conventional.
Save Our Seeds has reinforced the “freedom of choice” argument, warning that removing traceability makes corporate accountability virtually impossible. Similarly, IFOAM Organics Europe argues the negotiated outcome still falls short on the “coexistence” measures necessary to protect organic integrity and avoid contamination disputes. They see the lack of a full patent ban as a “time bomb,” as the transparency measures currently in place do not prevent the concentration of the seed market. The European Non-GMO Industry Association (ENGA)maintains the legislation removes key safeguards for much of the NGT-1 stream and warns that the patent issues remain fundamentally unresolved.
Slow Food Europe has emerged as a major voice of opposition, arguing that the deregulation of NGTs threatens “food sovereignty” and the survival of traditional, locally-adapted seed varieties that cannot compete with patented genetic inventions. They contend that by favoring large-scale industrial agribusiness, the EU is abandoning the small-scale producers who are the backbone of European food culture. Other groups have raised specific technical and environmental alarms:
-
- Friends of the Earth Europe explicitly links the loosening of controls to a breakdown in transparency and food safety accountability.
- The European Environmental Bureau emphasizes that by removing monitoring requirements, the EU is “flying blind” regarding the long-term impact of these crops on biodiversity.
- BeeLife European Beekeeping Coordination has raised alarms about the lack of specific risk assessments for pollinators, arguing that gene-edited traits could have cascading effects on honeybee health that the simplified verification process ignores.
- Testbiotech released a report in March 2026 arguing that the current direction exempts too many NGT plants from meaningful assessment and that the European Food Safety Authority (EFSA) is systematically underestimating the risks of “off-target” genetic effects.
Updated: 08/04/2026
